AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,567.00GBp
29 Aug 2014
Price Change (% chg)

87.50p (+1.95%)
Prev Close
4,479.50p
Open
4,530.00p
Day's High
4,667.50p
Day's Low
4,530.00p
Volume
3,698,557
Avg. Vol
2,169,185
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.36
Market Cap (Mil.): £56,526.72
Shares Outstanding (Mil.): 1,262.59
Dividend: 53.10
Yield (%): 3.79

Financials

  AZN.L Industry Sector
P/E (TTM): 46.25 32.64 33.56
EPS (TTM): 0.97 -- --
ROI: 5.03 18.00 17.31
ROE: 8.94 18.64 18.05
Search Stocks

FTSE inches higher, Tesco slumps after profit warning

LONDON, Aug 29 - Britain's top share index ended slightly higher on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks outpacing a sharp decline in retail stocks after another profit warning by Tesco .

11:55am EDT

FTSE steadies, Tesco slumps after profit warning

LONDON, Aug 29 - Britain's top share index steadied in cautious trading on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks offsetting weaker retailers after another profit warning by Tesco.

10:11am EDT

FTSE edges higher, stronger drugmakers outpace weak retailers

LONDON, Aug 29 - Britain's top share index edged higher in cautious trading on Friday, with stronger pharmaceutical stocks on renewed merger and acquisition talks outpacing weaker retailers after another profit warning by Tesco .

6:58am EDT

AstraZeneca boosted by start of new cancer drug trial

LONDON - Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

6:31am EDT

UPDATE 1-AstraZeneca boosted by start of new cancer drug trial

* AstraZeneca shares up 2 percent (Adds sales forecasts, detail on competitors, latest shares)

6:29am EDT

Hopes rise for AstraZeneca cancer drug with start of new trial

LONDON, Aug 29 - Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

4:21am EDT

Roche to buy U.S. biotech firm InterMune for $8.3 billion

LONDON/ZURICH - Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

24 Aug 2014

UPDATE 3-Roche to buy U.S. biotech firm InterMune for $8.3 bln

* Consensus 2019 sales for InterMune lung drug $1.04 bln (Adds comments from Roche CEO, analyst)

24 Aug 2014

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

21 Aug 2014

UPDATE 2-Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

(Adds details on drug, rival drugs, new treatment approach)

21 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Validea
$12.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks